Lessons learned after one year of COVID-19 from a urologist and radiotherapist view: A German survey on prostate cancer diagnosis and treatment.
Nina Natascha HarkeChristian WagnerRobert M HermannBoris A HadaschikJan Philipp RadtkeAlev Altay-LangguthStefan AufderklammChristian BachMartina Becker-SchiebeAndreas BlanaFrank BrunsStephan BuseStephanie E CombsChristina L EngelsEmad EzzibdehMarcel FiedlerLaura-Anna FischerMahmoud FarzatAlexander FrismannMatthias M HeckChristoph HenkenberensMarie C RoeschChristoph KädingGunther KlautkePhilipp KrausewitzMarkus A KuczykConrad LeitsmannSebastian LettmaierSamy MahjoubAndreas ManseckDaniel MedenwaldAndreas MeyerOliver MickeRudolf MoritzMarcel OttInga PetersSasa PokupicDaniel PorresFelix PreisserKathrin ReichelAndreas SchneiderChristian SchwentnerSergiu ScobioalaMichael TrussDaniel WegenerFelix WezelKay WillbornJörn H WittAndrea WittigMichael WittlingerHendrik A WolffVolker ZimmermannsHans ChristiansenPublished in: PloS one (2022)
While the diagnosis and therapy of PCa were affected in both waves of the pandemic, the interim increase between the peaks led to a higher total number of patients in 2020 than in 2019. Recommendations regarding prioritization and fractionation routines were implemented heterogeneously, leaving unexplored potential for future pandemic challenges.